Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Upright Clinical Microscope

By Drug Discovery Trends Editor | April 6, 2010

Olympus has unveiled its BX3 line of upright clinical and research microscopes with exclusive ergonomic and imaging features that provide unprecedented comfort, ease of use and accuracy. The all-new BX3 microscope lineup will deliver outstanding optical performance, value, reliability and eco-friendly operation.

Newly introduced are the BX43 System Microscope for clinical laboratory applications, the BX46 Clinical Microscope with exceptionally ergonomic design and fast observation, and the BX53 System Microscope for research/clinical applications. All three systems employ the company’s proprietary UIS2 optics, which deliver ultra-sharp, bright images and are manufactured from lead-free glass. The new systems succeed the immensely successful Olympus BX2 microscopes, which are among the most popular clinical microscopes in US laboratories.

“Customers who have enjoyed Olympus microscopes’ legendary optical performance, longevity and comfortable operation will recognize all the things they love in the new systems,” said Edward Lachica, Ph.D., director of product marketing, Scientific Equipment Group, Olympus America Inc. “They’ll also benefit from the intelligent integration of new features that make the accuracy, efficiency and ergonomics even better than before.”

Additional advancements in the design of the BX3 series allow users to record and share microscope magnification and setting information automatically for comparing, measuring and scaling images. There is even a handy exposure button that makes it possible for researchers to capture digital images without taking their hands off the microscope. Another new option is a tilting trinocular observation tube that provides comfortable, efficient operation when capturing photomicrographs.

The BX43 and BX46 are designed for efficiency and comfort in clinical applications. Their performance and value are enhanced through environmentally-conscious features including a bright LED lamp that offers halogen-like color fidelity, uses less energy and lasts approximately 20,000 hours. A Light Intensity Manager eliminates the need to make manual adjustments when changing magnifications. Users can select either left- or right-handed microscope operation for maximum flexibility.

New to both instruments is the world’s first optional tilting, telescoping and lifting observation tube, which easily allows users to adjust the height, front-to-back position and tilt angle of the eyepieces independently for the ultimate in comfortable observation.

The BX46 features the lowest stage height available – just three inches above the tabletop – for the ultimate in stress-free operation with reduced fatigue. The fixed stage design of the BX46 provides exceptional stability and accuracy in specimen positioning.

The BX53 research/clinical system offers new fluorescence optics and filters, including improved hard-coating technology and a unique fly’s eye array that delivers higher-quality images by providing more even illumination. It offers a unique motion sensor that detects when the user steps away from the instrument, automatically turning off the lamp after approximately 30 minutes, thus saving energy and providing longer lamp life. Both the BX43 and BX53 offer an optional new condenser that accommodates magnifications from 2x to 100x without requiring a swing-top lens.

Olympus America


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE